amyloidosis

EU Advisory Group Backs Orphan Drug Designation for Alnylam's ALN-TTRsc02 for ATTR Amyloidosis
Alnylam
amyloidosis
ALN-TTRsc02
Flag link:
Alnylam outshines Ionis with RNAi drug
Alnylam outshines Ionis with RNAi drug
BioPharma Dive
Alnylam
Ionis Pharmaceuticals
RNAi
Sanofi
Patisiran
amyloidosis
Flag link:
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
Alnylam Reports Positive Phase II Data for Patisiran (ALN-TTR02), an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR), and Initiates Phase III Trial
Yahoo/BusinessWire
Alnylam
Patisiran
amyloidosis
TTR-mediated amyloidosis
Flag link:
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
Alnylam Reports Positive Phase II Data for ALN-TTR02, an RNAi Therapeutic Targeting Transthyretin (TTR) for the Treatment of TTR-Mediated Amyloidosis (ATTR)
Yahoo/BusinessWire
ALN-TTR02
Alnylam
amyloidosis
TTR-mediated amyloidosis
Flag link:
Millennium starts Phase 3 trial for amyloidosis
Millennium starts Phase 3 trial for amyloidosis
Mass High Tech, MA
MLN9708
Millennium
amyloidosis
Flag link:
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Alnylam Pushes Forward In Amyloidosis After Pfizer Setback
Seeking Alpha
Alnylam
amyloidosis
Pfizer
ALN-TTR02
Flag link:
Alnylam initiates Phase II study of ALN-TTR02
Alnylam initiates Phase II study of ALN-TTR02
Pharmaceutical Business Review
Alnylam
ALN-TTR02
amyloidosis
Flag link: